|
Age (SD)
|
66.9 (11.0)
|
|
Male/Female (%)
|
214 (69.5)/94 (30.5)
|
|
Main language spoken at home (% English)
|
238/305 (78.0)
|
|
Australia as the country of birth
|
141/304 (46.4)
|
|
Body weight (IQR) kg
|
86.1 (72.8 – 101.3)
|
|
Height (SD) m
|
1.68 (0.10)
|
|
BMI (SD) kg/m2
|
30.7 (7.4)
|
|
Systolic blood pressure (SD) mmHg
|
134 (18)
|
|
Diastolic blood pressure (SD) mmHg
|
72 (11)
|
|
Active Smoker (%)
|
18/230 (7.8)
|
|
Diabetes duration (IQR) yrs.
|
17.0 (10.0 – 23.5)
|
|
Diabetes type (%)
|
|
type 1
|
28 (9.1)
|
|
type 2
|
271 (88.0)
|
|
other
|
9 (2.9)
|
|
CKD stage (KDIGO)%
|
|
3a
|
72 (23.4)
|
|
3b
|
79 (25.7)
|
|
4
|
76 (24.7)
|
|
5 (inclusive of 5D)
|
81 (26.3)
|
|
Dialysis (%)
|
59 (19.2)
|
|
Haemodialysis (%)
|
42 (71.1)
|
|
Peritoneal dialysis (%)
|
17 (28.9)
|
|
Other multi-morbidity
|
|
Hypertension (%)
|
291/308 (94.5)
|
|
Dyslipidaemia (%)
|
256/308 (83.1)
|
|
Ischemic Heart Disease (%)
|
143/304 (47.0)
|
|
Stroke (%)
|
38/305 (12.5)
|
|
Peripheral Vascular Disease (%)
|
82/304 (27.0)
|
|
Diabetic Retinopathy (%)
|
132/305 (43.3)
|
|
Diabetic Neuropathy (%)
|
108/305 (35.4)
|
|
Diabetic Nephropathy as a cause of CKD (%)
|
219/306 (71.6)
|
|
Biochemical Parameters
|
|
Haemoglobin (SD) g/L
|
122 (18)
|
|
HbA1c %
|
7.3 (6.4 – 8.3)
|
|
HbA1c (mmol/mol)
|
56 (47 – 67)
|
|
Total Cholesterol (IQR) mmol/L
|
3.9 (3.4 – 4.6)
|
|
LDL (IQR) mmol/L
|
1.8 (1.4 – 2.5)
|
|
HDL (IQR) mmol/L
|
1 (0.8 – 1.2)
|
|
Triglycerides (IQR) mmol/L
|
1.8 (1.2 – 2.5)
|
|
Potassium (SD) mmol/L
|
4.6 (0.6)
|
|
Calcium (SD) mmol/L
|
2.31 (0.14)
|
|
Phosphate (IQR) mmol/L
|
1.23 (1.08 – 1.46)
|
|
PTH (IQR) pmol/L
|
15.7 (7.8 – 30.6)
|
|
Medication Usage
|
|
Insulin only (%)
|
136 (44.2)
|
|
Non-insulin glucose lowering therapy only (%)
|
85 (27.6)
|
|
Both insulin and non-insulin glucose lowering therapy (%)
|
67 (21.8)
|
|
Diet only with other glucose lowering therapies (%)
|
20 (6.5)
|
|
Statin use (%)
|
248 (80.5)
|
|
Fibrate (%)
|
34 (11.0)
|
|
Use of any antihypertensive (%)
|
278 (90.3)
|
|
Use of ACEI and/or AT2RB (%)
|
185 (60.1)
|
|
Use of other antihypertensive besides an ACEI/AT2RB (%)
|
240 (77.9)
|
|
ESA use (%)
|
64 (20.8)
|
|
Iron supplementation (%)
|
57 (18.5)
|
|
Phosphate binder (%)
|
58 (18.8)
|
